Home > Healthcare > Medical Devices > Therapeutic Devices > Smart Insulin Pens Market

Smart Insulin Pens Market Share

Report ID: GMI8271
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Smart Insulin Pens Market Share

The smart insulin pens industry is consolidated in nature, with various large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products with improved efficiency and cost-effectiveness are among a key market strategy for smart insulin pen manufacturers. Some of the leading industry players including Medtronic plc, Novo Nordisk, and Ypsomed Group, among others have a substantial presence in the market.

Smart Insulin Pens Market Companies

Some of the eminent market participants operating in the smart insulin pens industry include:

Cambridge Consultants Ltd.
Eli Lilly and Company
Emperra GmbH
Jiangsu Delfu medical device Co., Ltd.
Medtronic plc
Novo Nordisk
Ypsomed Group

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global smart insulin pens industry was valued at around USD 850.6 million in 2023 and is estimated to reach USD 1.9 billion by 2032, attributed to factors such as the rising prevalence of diabetes coupled with enhanced awareness of self-management of diabetes.

The Bluetooth segment is anticipated to witness substantial expansion at 9.3% rate from 2024 to 2032 owing to a high level of accessibility and control over diabetes management for patients.

North America smart insulin pens market accounted for USD 329.3 million in 2023 and is predicted to witness substantial growth through 2032 owing to prevalence of both Type 1 and Type 2 diabetes, and the widespread reliance on insulin for effective diabetes management.

Cambridge Consultants Ltd., Eli Lilly and Company, Emperra GmbH, Jiangsu Delfu medical device Co., Ltd., Medtronic plc, Novo Nordisk, and Ypsomed Group.